Collectively, our findings indicate that melanoma‐derived IL‐1β might represent only a small fraction of the IL‐1β within the tumor microenvironment and targeting NLRP3 would affect primarily immune rather than tumor cells. The gene discussed is NLRP3; the disease is melanoma.